Institute for Wealth Management LLC. Has $330,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Institute for Wealth Management LLC. lowered its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 49.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,023 shares of the company's stock after selling 1,949 shares during the quarter. Institute for Wealth Management LLC.'s holdings in Zoetis were worth $330,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis during the 3rd quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the third quarter worth $33,000. Dunhill Financial LLC lifted its position in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after buying an additional 75 shares during the last quarter. Finally, Quarry LP grew its position in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company's stock valued at $36,000 after buying an additional 153 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

NYSE:ZTS traded down $0.21 during mid-day trading on Tuesday, reaching $171.73. 1,521,650 shares of the stock were exchanged, compared to its average volume of 2,627,942. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The business has a fifty day moving average price of $169.48 and a 200 day moving average price of $179.39. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The firm has a market capitalization of $77.48 billion, a PE ratio of 32.27, a PEG ratio of 2.72 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company's quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.36 EPS. Research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. This is a positive change from Zoetis's previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis's dividend payout ratio is 37.59%.

Analyst Ratings Changes

A number of brokerages have issued reports on ZTS. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price on the stock. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Morgan Stanley dropped their target price on Zoetis from $248.00 to $243.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Finally, Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target for the company. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis has an average rating of "Buy" and an average price target of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.